United Neuroscience Competitors and Similar CompaniesClear all
Alexion Pharmaceuticals's competitors and similar companies include Pharming Group and Immatics.
 Alexion Pharmaceuticals Alexion (also known as Alexion, AstraZeneca Rare Disease) is a biopharmaceutical company engaged in therapies for rare diseases. |  Pharming Group Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases. |  Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. | |
Founding Date | Founding Date 1992 | Founding Date 1988 | Founding Date N/A |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Boston, US HQ Frenchs Forest, AU Wien, AT Elsene, BE São Paulo, BR Vaughan, CA Shanghai, CN see more | Locations Leiden, NL HQ Leiden, NL | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US |
Employees | Employees 10,6006% increase | Employees 404 | Employees 29723% increase |
Valuation ($) | Valuation ($) 40.3 b | Valuation ($) 590.3 m | Valuation ($) 1.1 b |
Financial | |||
Revenue (est.) | Revenue (est.) $6.1b (FY, 2020) | Revenue (est.) $376.1m (FY, 2025) | Revenue (est.) €48.3m (FY, 2025) |
Cost of goods | Cost of goods $553.5m (FY, 2020) | Cost of goods $41.6m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $5.5b (FY, 2020) | Gross profit $341m (FY, 2025) | Gross profit €53m (FY, 2025) |
Net income | Net income $603.4m (FY, 2020) | Net income $2.5m (FY, 2025) | Net income (€196.4m) (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
Pharming Group
HQ
Leiden, NL
Employees
404
Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases.
View companyImmatics
HQ
Tübingen, DE
Employees
297↑ 23% increase
Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer.
View company